eli lilly glp-1 agonist Medscape | Orforglipron, Lilly's investigational oral glucagon-like peptide 1 receptor (GLP-1 RA), achieved positive phase 3 results for Medscape - Orforglipron, Eli Lilly's

The mechanisms of most currently used obesity treatments predominantly focus on appetite suppression

To avoid redundancies across similar articles, this paper sought to instead further summarize and highlight specific key similarities and differences among important and overlapping theme categories between previously published works on the topic

Writers advise that the ASA guidelines should strongly emphasize the current absence of sufficient evidence

The side effect profile is well-documented, serious adverse events are rare, and long-term data is accumulating

[DOI] [PMC free article] [PubMed] [Google Scholar] 78

Cardiovasc Ther (2012) 30(3):e14655